Navigation Links
UCF professor develops vaccine to protect against black plague bioterror attack
Date:11/13/2008

in the Congo and another 124 were infected before the epidemic was stopped. In the mid 1990s more than 400 people were infected in India.

Although human trials are still needed, Daniell is confident the vaccine will work for the bubonic and pneumonic plague based on animal studies. Pneumonic plague is spread through the air. Without treatment a person can die within days. Bubonic plague is the more common form and is transmitted through fleabites and kills about 70 percent of those infected within 4-7 days if not treated. It was the version that ravaged Europe. If the early findings hold true, this vaccine could mean an extra layer of protection against natural epidemics and man-made threats.

The Centers for Disease Control lists the pneumonic plague as a potential bioterrorism agent because of the speed of which it can be spread and its 60 percent fatality rate if not treated early enough with an aggressive array of antibiotics.

Daniell was inspired to investigate an oral vaccine for the plague because of his pioneering work in diabetes. He and his team genetically engineered tobacco and lettuce plants with the insulin gene and then administered freeze-dried plant cells to five-week-old diabetic mice for eight weeks. By the end of this study, the diabetic mice had normal blood and urine sugar levels, and their cells were producing normal levels of insulin.

Daniell figured the same approach might work with a vaccine. He genetically engineered plant cells with a protein found on the outside of Yersinia pestis. The vaccine was inside the plant cells, which were given to the rats. The vaccine was protected from digestion in the stomach and was then absorbed in the gut. It kick started the immune system into producing antibodies, which protects against the deadly disease. Three to five doses seem to do the trick.

Daniell, who was born and raised in India, has dedicated his life to finding treatments and cures to diseases tha
'/>"/>

Contact: Zenaida Gonzalez Kotala
zkotala@mail.ucf.edu
407-446-6567
University of Central Florida
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
2. Stuart Parkin first distinguished professor at Eindhoven University of Technology
3. UCF professor develops vaccine to protect against black plague bioterror attack
4. Professor-turned-producer learns the movie biz
5. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
6. Professor Toh-Ming Lu named fellow of the Materials Research Society
7. Professor Straufs research is Nature Photonics’ cover article
8. Cambridge Major Appoints Professor John Hartwig as Scientific Advisor
9. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
10. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... - Epizyme, Inc., a company leading the discovery and ... today announced the publication of breakthrough new research in ... (USA). The discovery, centered on the epigenetic ... of basic science into targeted therapies for the safe ...
... it took his computer to boot up, Klui began to ... store enormous quantities of data, but they are slow; every ... information is transferred from the hard disk into RAM (random ... and energy consumption runs into the hundreds of millions of ...
... 15, 2010 Celladon Corp., a biopharmaceutical company ... treatments for cardiovascular diseases, today announced that 12-month ... of MYDICAR® demonstrated significant improvements in clinical outcomes ... patients treated with the genetically-targeted enzyme replacement therapy. ...
Cached Biology Technology:Epizyme identifies novel opportunity for treatment of genetically defined human B-cell lymphomas 2Racetrack memory 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... created by researchers at the San Diego Supercomputer Center ... scientists to study evolutionary relationships among large populations of ... having to understand how to operate large, complex computer ... CIPRES (Cyberinfrastructure for Phylogenetic RESearch) Gateway, is ...
... The Cystic Fibrosis Foundation has awarded a Marshall University ... Dr. Hongwei Yu, professor in the Department of Biochemistry ... of Medicine, will help further his lab,s work to ... in the lungs of cystic fibrosis (CF) patients. ...
... policies governing the storage and use of surplus blood samples ... process range from explicit to non-existent, leaving many parents ill-informed ... according to a team led by a member of the ... from the University of Utah. A report on their analysis ...
Cached Biology News:SDSC's CIPRES Gateway provides window to the past -- and fast 2SDSC's CIPRES Gateway provides window to the past -- and fast 3Cystic Fibrosis Foundation funds Marshall research 2Most states unclear about storage, use of babies' blood samples, new study finds 2Most states unclear about storage, use of babies' blood samples, new study finds 3Most states unclear about storage, use of babies' blood samples, new study finds 4
...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Biology Products: